Predicta Biosciences

Last night was above par as we celebrated the holiday spirit with our incredible team and had fun putting around! A special congratulations to François Aguet for his big win of the night! This season, we're reminded of the importance of giving and our commitment to bringing innovative solutions to improve patient outcomes. Celebrating the achievements of 2024 and excited for what the future holds. Wishing everyone a joyful holiday season and a prosperous year ahead!

⭐ Welcome to Predicta Biosciences, Julian Hess! 🌟 We are excited to have Julian join our team as Principal Computational Biologist. With an impressive background from the Getz Lab at the Broad Institute, Julian brings a wealth of computational biology and cancer genomics knowledge. His tenure in Gaddy Getz’s group spans various topics, from basic cancer biology to sequencing technology, statistical algorithms, and computational infrastructure. As he embarks on this new journey with us, he strongly aligns with our mission to translate his extensive learning into tangible solutions for patients.

  🍂 Happy Thanksgiving from all of us at Predicta Biosciences! 🍂 We are grateful for our incredible team and the hard work each member contributes to our mission. Our recent Thanksgiving lunch was a wonderful opportunity to celebrate our achievements and the strong bonds we've built together.   As we reflect on this season of gratitude, we want to thank our investors, clinicians, partners, and especially patients for your support. We look forward to continuing our journey together and positively impacting patients.   Wishing everyone a joyful and fulfilling holiday! 🦃✨   #Gratitude #TeamPredicta

We are pleased to announce that Molly Hurley has accepted the Catalyst Fellowship. Congratulations, Molly! We look forward to seeing the valuable work you’ll do as a Catalyst Fellow. We're proud to support you on this journey and anticipate the positive impact you will have.

We are excited to announce that Aparna Raval, PhD, SVP of Translational Research, will attend the upcoming #ASH24 meeting. If you are interested in learning more about our company and our GenoPredicta and Immunopredicta platforms for multiple myeloma and other hematological malignancies, please reach out to schedule a meeting. We are looking forward to connecting with you! To learn more about our precision medicine solutions, visit our website at https://lnkd.in/ejKDK3Ss. #ASH2024 #TranslationalResearch #Hematology   Email: info@predictabiosciences.com

This week, we held our first annual summit at Predicta Biosciences—a milestone moment where our entire team came together to unite around our mission of providing impactful solutions for patients. We feel incredibly fortunate to have a team with such diverse expertise, bringing unique insight and perspectives to the table. The thoughtful and inspiring discussions we shared have energized us to move forward with purpose, and we're more motivated than ever to execute on our mission. Kate Caves, Doron Lipson, Karen Lee Sobol,Irene Ghobrial, Romanos Sklavenitis-Pistofidis, Kenneth C. Anderson, MD, Aparna Raval, PhD, Danielle Sookiasian, François Aguet, Molly Hurley

🚀 New Chapter, Same Name, Same Mission. We're excited to announce our new Predicta Biosciences brand today! As we get closer to launching our first product GenoPredicta Multiple Myeloma Diagnostic Test next year, we're transforming our identity to reflect our core values of patient centricity, innovation, and collaboration. Stay tuned for more updates as we embark on this exciting new journey! #rebrand #biotech #innovation #patientcentricity #multiplemyeloma #genopredicta

🙏 A huge thank you to the BrightEdge - American Cancer Society team for hosting such impactful events and to Farnaz B. for moderating a fantastic session. It was a true pleasure to meet ACS President Karen Knudsen MBA PhD and we are inspired by her leadership and dedication to advancing innovation in healthcare. From the BEE | Pitch Event, where we showcased Predicta Biosciences advancements, to the insightful panel discussion on overcoming the "innovation impasse," we were energized by the commitment to fostering healthcare startups and making a real impact in patient outcomes. 📣 Thank you to Wilson Sonsini Goodrich & Rosati, Laurie McNamara and Jennifer Fang for your continued support and sponsorship of these transformative events.

It was honor to join the panel discussion, Breaking Down Barriers: Fostering Innovation in Healthcare, hosted by BrightEdge - American Cancer Society #ConvergeOnCancer Summit. Our conversation centered around the unique challenges faced by healthcare startups and explored practical strategies to support entrepreneurs in driving impactful innovation. According to our poll, financial constraints emerged as the greatest barrier to advancing cancer innovation, followed by regulatory hurdles, operational challenges, market demand limitations, and a lack of collaboration across stakeholders. To overcome these obstacles, we emphasized the importance for early-stage companies to surround themselves with advisors who have firsthand experience in bringing products to market. Building close, strategic relationships with investors and aligning with those who share a long-term belief in the product’s potential are also key factors in paving the way for success. Farnaz B. BrightEdge - American Cancer Society , Bianca Scimemi, Carol Curtis, Ph.D., and the fellow panelist Jennifer Fang, Kate Caves, Dawn Mattoon, William Dahut #BEConvergeOnCancerSummit American Cancer Society

Thrilled to have been part of the recent Myeloma Committee, where Valentina Nardi delivered an insightful presentation on our work! A big thank you to Saad Z. Usmani for the kind invitation. We are inspired by the innovative trials being conducted in the myeloma space and excited for Predicta Biosciences to contribute to these efforts. #Myeloma #Oncology #Innovation #Collaboration